U.S. markets closed
  • S&P 500

    4,482.73
    -50.03 (-1.10%)
     
  • Dow 30

    34,715.39
    -313.26 (-0.89%)
     
  • Nasdaq

    14,154.02
    -186.23 (-1.30%)
     
  • Russell 2000

    2,024.04
    -38.75 (-1.88%)
     
  • Crude Oil

    86.29
    -0.67 (-0.77%)
     
  • Gold

    1,839.80
    -3.40 (-0.18%)
     
  • Silver

    24.53
    +0.30 (+1.23%)
     
  • EUR/USD

    1.1313
    -0.0033 (-0.29%)
     
  • 10-Yr Bond

    1.8330
    +0.0060 (+0.33%)
     
  • GBP/USD

    1.3600
    -0.0011 (-0.08%)
     
  • USD/JPY

    114.1040
    -0.2490 (-0.22%)
     
  • BTC-USD

    41,281.32
    -544.38 (-1.30%)
     
  • CMC Crypto 200

    992.43
    -2.83 (-0.28%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

CNBC's Final Trades: Fiserv, ResMed, Monster Beverage And This Semiconductor Company

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • FISV
  • RMD
  • MNST

On CNBC’s “Halftime Report Final Trades,” Jenny Harrington of Gilman Hill Asset Management said Fiserv Inc (NASDAQ: FISV) belongs to its growth portfolio.

The stock is trading at 16 times earnings and has the potential for 15% earnings growth ahead, Harrington said. The stock is “wildly oversold,” she added.

Another trader in the show named Qualcomm, Inc. (NASDAQ: QCOM), saying that its upcoming analyst day should be a catalyst.

Joseph Terranova of Virtus Investment Partners cited ResMed Inc. (NYSE: RMD) as a top pick, noting the positives as being a San Diego-based medical equipment company with a focus on sleep disorder.

Pete Najarian named Monster Beverage Corp (NASDAQ: MNST). “I see some call buying in there and I think this stock’s going higher,” he commented.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.